- Home
- CGTX vs ICCC Comparison
CGTX vs ICCC Comparison
Compare CGTX & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- ICCC
- Stock Information
- Founded
- CGTX 2007
- ICCC 1982
- Country
- CGTX United States
- ICCC United States
- Employees
- CGTX N/A
- ICCC N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- ICCC Health Care
- Exchange
- CGTX Nasdaq
- ICCC Nasdaq
- Market Cap
- CGTX 53.4M
- ICCC 60.1M
- IPO Year
- CGTX 2021
- ICCC 1987
- Fundamental
- Price
- CGTX $1.54
- ICCC $6.10
- Analyst Decision
- CGTX Strong Buy
- ICCC
- Analyst Count
- CGTX 3
- ICCC 0
- Target Price
- CGTX $2.83
- ICCC N/A
- AVG Volume (30 Days)
- CGTX 8.5M
- ICCC 14.7K
- Earning Date
- CGTX 08-07-2025
- ICCC 08-14-2025
- Dividend Yield
- CGTX N/A
- ICCC N/A
- EPS Growth
- CGTX N/A
- ICCC N/A
- EPS
- CGTX N/A
- ICCC 0.20
- Revenue
- CGTX N/A
- ICCC $28,274,756.00
- Revenue This Year
- CGTX N/A
- ICCC N/A
- Revenue Next Year
- CGTX N/A
- ICCC N/A
- P/E Ratio
- CGTX N/A
- ICCC $30.42
- Revenue Growth
- CGTX N/A
- ICCC 21.75
- 52 Week Low
- CGTX $0.22
- ICCC $3.34
- 52 Week High
- CGTX $1.97
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- CGTX 77.80
- ICCC 42.37
- Support Level
- CGTX $1.15
- ICCC $5.99
- Resistance Level
- CGTX $0.74
- ICCC $6.90
- Average True Range (ATR)
- CGTX 0.19
- ICCC 0.43
- MACD
- CGTX 0.09
- ICCC -0.00
- Stochastic Oscillator
- CGTX 69.59
- ICCC 13.51
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.